Nykredit A S Makes New Investment in AbbVie Inc. $ABBV

Key Points

• Nykredit A/S acquired 640,558 AbbVie shares during the second quarter, valued at approximately $161.2 million. Institutional investors collectively own 70.23% of the company.
• AbbVie reported quarterly EPS of $3.65, exceeding estimates, while revenue rose 10.2% year over year to $16.99 billion. The company issued third-quarter 2026 EPS guidance of $3.84–$3.88.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $275.95, while AbbVie’s quarterly dividend is $1.73 per share, representing a 2.8% annualized yield.

Nykredit A S purchased a new position in AbbVie Inc. (NYSE:ABBV - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 640,558 shares of the company's stock, valued at approximately $161,190,000.

Several other institutional investors and hedge funds have also made changes to their positions in ABBV. Litman Gregory Wealth Management LLC acquired a new stake in AbbVie in the fourth quarter worth approximately $28,000. Imprint Wealth LLC increased its position in shares of AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock valued at $29,000 after purchasing an additional 45 shares during the period. Burk Holdings LLC bought a new stake in shares of AbbVie in the 2nd quarter worth $30,000. IFC & Insurance Marketing Inc. bought a new stake in shares of AbbVie in the 4th quarter worth $31,000. Finally, Abound Financial LLC acquired a new stake in shares of AbbVie in the fourth quarter valued at $32,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Up 0.9%

Shares of NYSE ABBV opened at $251.04 on Thursday. The stock's fifty day simple moving average is $254.66 and its 200 day simple moving average is $230.55. The stock has a market capitalization of $443.53 billion, a price-to-earnings ratio of 70.92, a PEG ratio of 1.13 and a beta of 0.29. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the business posted $2.97 earnings per share. AbbVie's revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts anticipate that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's dividend payout ratio (DPR) is 195.48%.

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ABBV. UBS Group raised their target price on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a research note on Monday, July 13th. Wall Street Zen downgraded shares of AbbVie from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 5th. Weiss Ratings upgraded shares of AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a research report on Tuesday, August 4th. BMO Capital Markets lifted their price objective on shares of AbbVie from $258.00 to $300.00 and gave the stock an "outperform" rating in a research note on Monday, July 13th. Finally, Piper Sandler boosted their target price on shares of AbbVie from $298.00 to $303.00 and gave the stock an "overweight" rating in a report on Thursday, August 20th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $275.95.

AbbVie Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott's diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie's immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.